1. Swimming for Duchenne

    Posted on August 20, 20147:02 pm

      CureDuchenne and the Duchenne Therapy Network are pleased to provide a video and educational information on the swimming activities for those with Duchenne muscular dystrophy. The pool is great for those with Duchenne.  It provides many benefits including: •             buoyancy to reduce the stress on muscles and joints •             mild resistance for low grade Read more »

  2. Prosensa is working towards long-term access to drisapersen

    Posted on August 15, 20144:27 pm

    CureDuchenne is pleased to share the latest update to patient groups from Prosensa, which outlines their progress to date, as well as future plans. CureDuchenne announced earlier in the week our $7 million collaboration with Prosensa to help speed access to treatments for Duchenne muscular dystrophy.   Dear Patient Group Representative, As previously communicated, Prosensa received Read more »

  3. Accelerating Access to Duchenne Drug Candidates

    Posted on August 12, 20144:23 pm

    Yesterday Prosensa and CureDuchenne announced an extension of our collaboration and a path to provide access to four experimental drugs for Duchenne patients. Ten years ago, CureDuchenne provided funding to Prosensa which allowed the company to move forward with their preclinical work and translate their exon skipping compounds into human clinical trials.  Since September 2013, Read more »

  4. Dr. Flanigan’s Duplication 2 Duchenne Mutation – Nature Medicine

    Posted on August 11, 20142:10 pm

    We are very excited to see that Dr. Kevin Flanigan’s work on a rare Duchenne mutation, a duplication on exon 2, was published in Nature Medicine.  This prestigious magazine reported on two advances in his current work which was supported by CureDuchenne. The first was the successful creation of a new mouse model of Duchenne Read more »

  5. An Update for the Duchenne Muscular Dystrophy Patient Community: Eteplirsen & Follow-On DMD Drug Candidates

    Posted on August 8, 20144:44 pm

    CureDuchenne is pleased to share the following information from Sarepta Therapeutics. They provided a summary of the regulatory developments and clinical updates. Sarepta is dedicated to helping DMD patients and their families, and we are committed to working as fast as possible to move our eteplirsen and follow-on DMD programs forward. We know the patient Read more »